Lausanne university hospital and university of Lausanne, Lausanne, Switzerland.
National Medical Research Center of Cardiology, Moscow, Russia.
J Hypertens. 2022 Jul 1;40(7):1388-1393. doi: 10.1097/HJH.0000000000003158. Epub 2022 Jun 10.
To assess whether a genetic risk score (GRS) for high SBP is associated with poor control of hypertension.
Data from the four waves of a population-based, prospective study conducted in Lausanne, Switzerland. Control of hypertension was defined based on SBP less than 140 mmHg and DBP less than 90 mmHg. A weighted GRS was computed from 362 SNPs.
Overall, 1097 (51% men, mean age 61 years), 1126 (53% men, age 65 years), 1020 (52% men, age 69 years) and 809 (50% men, age 71 years) participants treated for hypertension were selected from the baseline (2003-2006), first (2009-2012), second (2014-2017) and third (2018-2021) surveys. Hypertension control rates were 50, 58, 52 and 59% for the baseline, first, second and third surveys, respectively. No association was found between GRS and hypertension control: multivariate-adjusted mean ± standard error for controlled vs. uncontrolled participants: 9.30 ± 0.09 vs. 9.50 ± 0.09 ( P = 0.12); 9.32 ± 0.08 vs. 9.53 ± 0.10 ( P = 0.10); 9.17 ± 0.08 vs. 9.34 ± 0.11 ( P = 0.22), and 9.18 ± 0.09 vs. 9.46 ± 0.11 ( P = 0.07) for the baseline, first, second and third surveys, respectively. Power analysis showed that a minimum of 3410 people treated for hypertension would be necessary to detect an association between the GRS and hypertension control rates. Notably, positive associations between the GRS and SBP levels were found among participants not treated for hypertension, with Spearman correlations ranging between 0.05 and 0.09 (all P < 0.05).
Using a GRS associated with SBP levels is not predictive of hypertension control. The use of GRS for hypertension management is not warranted in clinical practice.
评估收缩压(SBP)高的遗传风险评分(GRS)是否与高血压控制不良有关。
本研究数据来自瑞士洛桑进行的一项基于人群的前瞻性研究的四个波次。高血压的控制定义为 SBP<140mmHg 和 DBP<90mmHg。从 362 个 SNP 中计算加权 GRS。
共从基线(2003-2006 年)、第一次(2009-2012 年)、第二次(2014-2017 年)和第三次(2018-2021 年)调查中选择了 1097 名(51%为男性,平均年龄 61 岁)、1126 名(53%为男性,年龄 65 岁)、1020 名(52%为男性,年龄 69 岁)和 809 名(50%为男性,年龄 71 岁)接受高血压治疗的参与者。基线、第一次、第二次和第三次调查中高血压控制率分别为 50%、58%、52%和 59%。GRS 与高血压控制之间没有关联:多变量调整后,与未控制参与者相比,控制参与者的平均值±标准误差为 9.30±0.09 vs. 9.50±0.09( P = 0.12);9.32±0.08 vs. 9.53±0.10( P = 0.10);9.17±0.08 vs. 9.34±0.11( P = 0.22),以及 9.18±0.09 vs. 9.46±0.11( P = 0.07),分别为基线、第一次、第二次和第三次调查。功效分析表明,需要至少 3410 名接受高血压治疗的患者才能检测到 GRS 与高血压控制率之间的关联。值得注意的是,在未接受高血压治疗的参与者中,GRS 与 SBP 水平之间存在正相关,Spearman 相关系数在 0.05 到 0.09 之间(均 P<0.05)。
使用与 SBP 水平相关的 GRS 不能预测高血压的控制。在临床实践中,不支持使用 GRS 进行高血压管理。